Newbury Pharmaceuticals AB (NEWBRY) — Cash Flow Reinvestment Rate
Latest as of February 2026:
0.00x
Newbury Pharmaceuticals AB (NEWBRY) has a Cash Flow Reinvestment Rate of 0.00x as of February 2026, reinvesting Skr0.00 (capex Skr0.00 ) from operating cash flow of Skr2.26 Million. Check NEWBRY cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
0.00x
(Capex + Investments) / Operating CF
Total Reinvested
Skr0.00
Capex + Investments
Operating Cash Flow
Skr2.26 Million
SEK
Capital Expenditures
Skr0.00
SEK
Annual Cash Flow Reinvestment Rate for Newbury Pharmaceuticals AB (None–None)
Year-by-year capital reinvestment analysis for Newbury Pharmaceuticals AB. For live market cap and broader valuation context, see NEWBRY stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (SEK) | Operating CF | Capex | YoY Change |
|---|
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow